{
    "nct_id": "NCT04381832",
    "official_title": "A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer",
    "inclusion_criteria": "* Male participants; age ≥ 18 years\n* Metastatic castrate-resistant prostate cancer while on anti-androgen treatment with castrate levels of testosterone (≤1.7 nanomoles per liter [nmol/L] or 50 nanograms per deciliter [ng/dL])\n* Measurable or non-measurable disease as per radiographic evaluation\n* Participants with measurable disease may require a fresh tumor biopsy at study entry\n* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1\n* Life expectancy of at least 3 months\n* Adequate hematologic and end-organ function\n* Human immunodeficiency virus (HIV), Hepatitis B, and C test results negative prior to first study treatment\n\nInclusion Criteria for Participants receiving an enzalutamide-containing treatment\n\n* Disease progression after prior treatment with abiraterone\n\nInclusion Criteria for Participants receiving a docetaxel-containing treatment\n\n* Disease progression after prior androgen synthesis inhibitor therapy\n\nInclusion Criteria for all other Participants\n\n* Disease progression after prior androgen synthesis inhibitor treatment and up to 2 prior lines of taxane chemotherapy\n\nGeneral\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with immune checkpoint blockade therapy\n* Prior anticancer treatment including approved agents, systemic radiotherapy, or investigational therapy, within 2-4 weeks prior first study treatment\n* Corrected QT interval (QTc) ≥480 msec using Fredericia's QT correction formula (based on an average of triplicate recordings)\n* Prior allogeneic stem cell or solid organ transplantation\n* Prior treatment with drugs that stimulate the immune system within 4 weeks prior to first study treatment\n* Prior treatment with drugs that suppress the immune system within 2 weeks prior to first study treatment\n* Received a live, attenuated vaccine within 4 weeks prior to first study treatment, or may need to receive a vaccine during study treatment\n* Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid - CSF (leptomeningeal disease)\n* Prior pulmonary fibrosis, pneumonia, or pneumonitis\n* Cancer other than prostate within 2 years prior to study entry, except for some cancers with a low risk of spreading like non-melanoma skin\n* Prior treatment with an agent targeting the adenosine pathway\n* No oral or IV antibiotics within 2 weeks prior to first study treatment\n* No severe infection within 4 weeks prior to first study treatment\n* No clinically significant cardiac disease\n* Inability to swallow medications\n\nExclusion Criteria for Participants receiving an enzalutamide-containing treatment\n\n* Prior treatment with docetaxel, cabazitaxel, or other taxane chemotherapy (prior docetaxel [up to 6 cycles] for hormone-sensitive prostate cancer is allowed if the last dose was at least 6 months prior to study treatment initiation)\n* Prior treatment with enzalutamide or similar therapy other than abiraterone\n* Active or history of autoimmune disease or immune deficiency\n* History of severe allergic reactions to antibody therapy\n* Concomitant use of a medication prohibited by the protocol (including certain transporter substrates as well as known strong CYP3A4 inducers and CYP3A4 inhibitors) within 4 weeks prior to and throughout study treatment\n\nExclusion Criteria for Participants receiving a docetaxel-containing treatment\n\n* Prior treatment with docetaxel, cabazitaxel, or other taxane chemotherapy\n* Active or history of autoimmune disease or immune deficiency\n* History of severe allergic reactions to antibody therapy\n* Concomitant use of a medication prohibited by the protocol (including certain transporter substrates as well as known strong CYP3A4 inducers and CYP3A4 inhibitors) within 4 weeks prior to and throughout study treatment\n\nExclusion Criteria for all other Participants\n\n* Prior treatment with docetaxel, cabazitaxel, topoisomerase 1 inhibitors, or other taxane chemotherapy\n* Active or history of autoimmune disease or immune deficiency\n* History of severe allergic reactions to antibody therapy\n* Concomitant use of a medication prohibited by the protocol (including certain transporter substrates as well as known strong CYP3A4 inducers and CYP3A4 inhibitors) within 4 weeks prior to and throughout study treatment",
    "miscellaneous_criteria": "General"
}